Abi Carter is timing the partnership with the release of her upcoming album.
Abi Carter, IEHP
American Idol’s 2024 winner is teaming up with Inland Empire Health Plan (IEHP) to promote mental health awareness.1 Abi Carter, an Indio, California, native, is timing the partnership with the release of her first album on November 15. The campaign will be focused on promoting wellness check-ins for young people.
In a press release, IEHP chief executive officer Jarrod McNaughton said, “Besides being a talented musician, Abi has a passion for wellness. Her social media messages about healing, self-care and community, in addition to her strong connection to young audiences, make her the perfect partner to promote these important discussions."
Carter added, “Growing up in Indio as a former member of IEHP, I've seen firsthand the need for greater mental health support, especially for young people. I'm honored to partner with IEHP to spread awareness and help open the conversation around mental wellness."
IEHP is also involved in other charitable activities. In October, the organization announced that it had raised $25,000 for breast cancer research as part of its More Than Pink Walk.2
In a press release issued at the time, IEHP’s chief operating officer Susie White said, “Coming together as an organization to walk reminds me of the family, friends and community who are impacted by breast cancer. I walk for my mom and to remind others that they are not alone in their journey. Together, we can make a lasting impact one step at a time."
Jill Eaton, executive director of the nonprofit's Inland Empire and Nevada region, added, “We are honored to have IEHP, the 2024 Pilar sponsor for the Susan G. Komen Inland Empire MORE THAN PINK walk, [on board]. Together we are making a profound impact in the fight against breast cancer. Supporting individuals in our community who are facing breast cancer is essential to our mission, and we do not do this alone."
"Participation in 'Team IEHP Goes Pink' grows every year, and the generosity of our team never ceases to amaze me," said Rebecca Mayer, director of operations administration for IEHP. "I'm lucky to work for an organization where everyone believes in opening access to optimal care."
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.